RRM1表达与吉西他滨治疗晚期NSCLC疗效关系:Meta分析

Relationship between RRM1 expression and therapeutic effects of gemcitabine for advanced non-small cell lung carcinoma(NSCLC):a meta-analysis

目的对晚期非小细胞肺癌（Nscrc）患者核糖核苷还原酶调节因子1（RRMl）表达水平与吉西他滨化疗疗效的相关性进行Meta分析。方法通过计算机检索中国知网（CNKI）数据库、万方数据库、PubMed、EMBASE和ASCO数据库，纳入文献为以中英文发表的全文。收集比较不同RRMl表达水平（高表达／阳性与低表达／阴性）的晚期NSCLC患者对接受含吉西他滨化疗方案的反应率的文章。采用Cochrane协作网RevMan5．0软件进行分析。结果最终纳入11项研究，共515例患者。235例为RRMl高表达／阳性患者，合并有效率为17．9％，280例RRMl低表达／阴性患者，合并有效率为44．3％。异质性检验结果显示各研究不存在统计学异质性（x2=10．50，p=o．40，I2=5％）。采用固定效应模型对文献进行定量综合分析，合并OR值为3．70，95％可信区间为2．43～5．63，Z=6．11，P〈0．00001。结论在晚期NSCLC患者中，RRMl低表达／阴性者接受吉西他滨化疗的疗效优于RRMl高表达/阳性者。

Objective The present study presents ameta analysis on the correlation between the expression of ribonucleoside reductase regulatory factor I（RRM1） and the therapeutic effects of gemcitabine for advanced non-small cell lung cancer （NSCLC）. Methods Chinese and English publications were retrieved from the CNKI, WANFANG, PubMed, EMBASE, and ASCO database with an electronic computer to compare the response rate of the advanced NSCLC patients with different RRM1 expression level （high expression/positive and low expression/negative） to gemcitabine chemotherapy. The Cochrane Collaboration＇s RevMan 5.0 software was adopted for the analysis. Results Eleven studies, with a total of 515 patients, were identified. The number of patients with high/positive RRM1 protein expression was 235, and the amalgamated effective rate was 17.9%. The number of patients with low/negative RRM1 protein expression was 280, and the amalgamated effective rate was 44.3%. Heterogeneity test showed no statistical heterogeneity among studies （Xz=10.50, P=0.40,/2=5%）. The fixed effect model was adopted for a comprehensive quantitative analysis of the studies, and it showed that the combined odds ratio （OR） was 3.70, with a 95% confidence interval of 2.43 to 5.63, Z=6.11, P〈0.00001. Conclusion The patients with low/negative RRM1 expression in advanced NSCLC were more sensitive to gemcitabine chemotherapy compared with patients having high/positive RRM1 expression.